Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-523"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-523"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5242
lpv:speaker	lp:Richard Seeber2
lpv:spokenAs	substitute; REGI (2009-07-16--2012-01-18)3,3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3,3 unknown; Österreichische Volkspartei (2009-07-14--2014-06-30)3,3 substitute; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3,3 member; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3,3 member_of_the_bureau; EPP (2009-07-24--2014-06-30)3,3 member; ENVI (2009-07-16--2012-01-18)3,3
lpv:translated text	"For patients, easy access to factual and independent background information on medicinal products is essential and also plays an important role in the research into adverse reactions and in the market safety of prescription medicines. The new directive and regulation on pharmacovigilance will substantially improve transparency and access to such information. The basis of, and explanations for, any adverse reactions will now be collected from the whole of Europe by the European Medicines Agency. The storage and processing of this data and the establishment of web portals to facilitate access to it will substantially improve the opportunities for patients to find out about medicines and their adverse effects. Particularly when European citizens are travelling, they will not be reliant on any particular websites but, where necessary, will be able to obtain objective information in their own language. In order to guarantee independence and objectivity, however, the information will have to be approved by relevant approval authorities. On the other hand, this will also guarantee the freedom of advertising in respect of this information. The new drug facts box will identify active substances that have been approved for the first time. All these measures will increase transparency and make it easier for patients to find pharmaceutical information in a clear and uncomplicated manner."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph